In addition, loss[8p] and copy number gain of MCL1, an anti-apoptotic member alternative to Bcl-2, have been identified as potentially genes-first mechanisms of acquired venetoclax resistance in CLL [64]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.